Dr. Ronan Glynn:

We will need to wait and see how the HSE reallocates the vaccine to various cohorts and how it plans to deploy available vaccines, but AstraZeneca only accounts for approximately 20% of vaccines over the next eight weeks. A significant number of people who have not been vaccinated are eligible and will be eligible for AstraZeneca and a significant number of people will require a second dose of this vaccine.

All those people receiving AstraZeneca will leave the Pfizer, Moderna and, hopefully, Johnson & Johnson vaccines available for other groups of people. I hope, on the basis of last night's recommendations, the impact on the overall roll-out at population level should be minimal, when one looks forward to where we will be at the end of May or June. Obviously, there is an interruption this week but, hopefully, it can be addressed quite quickly.